National Health (Originator Brand) Amendment Determination 2016 (No. 8) (PB 105 of 2016) (Cth)

PB 105 of 2016

National Health (Originator Brand) Amendment Determination 2016 (No. 8)

National Health Act 1953

I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated       29^th     November 2016

______________________________________

LOUISE CLARKE
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

1. Name of Determination

   (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 8).

   (2)     This Determination may also be cited as PB 105 of 2016.

2. Commencement

   This Determination commences on 1 December 2016.

3. Amendments to PB 100 of 2015

   Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1, (after table item 16A)

insert:

16B	Aripiprazole	Abilify	Oral
		Abilfy Maintena	Injection

[2]   Schedule 1 (after table item 25)

Insert:

25A Bivalirudin Angiomax

[3]   Schedule 1 (table item 74A)

Repeal the item, substitute:

74A	Entecavir	Baraclude
74B	Eplerenone	Inspra

[4]   Schedule 1 (after table item 121)

Insert:

121A Itraconazole Sporanox Lozanoc

[5]   Schedule 1 (after table item 170)

Insert:

170A	Olmesartan with amlodipine	Sevikar 20/5 Sevikar 40/5 Sevikar 40/10
170B	Olmesartan with hydrochlorothiazide	Olmetec Plus

[6]   Schedule 1 (after table item 204)

Insert:

204A	Rivastigmine	Exelon	Oral
		Exelon Patch 5 Exelon Patch 10 Exelon Patch 15	Transdermal